Tromsø, Norway, December 21, 2023 - ArcticZymes Technologies ASA (OSE: AZT)
launches T7 RNA Polymerase

ArcticZymes Technologies (AZT) today announces the launch of its new product, T7
RNA Polymerase. Serving customers within the Molecular Tools segment, the T7 RNA
Polymerase is intended for use in molecular research and diagnostics. The enzyme
precedes the planned launch of a bioprocessing grade T7 RNA polymerase scheduled
for 2024.

The launch of the T7 RNA Polymerase is an example of ArcticZymes exploiting
synergies between its business segments. While the field of RNA therapeutics is
rapidly evolving, the T7 RNA Polymerase may support different research areas as
well as being a key component in various molecular diagnostic applications.

The T7 RNA Polymerase will be available for ordering during January 2024.

CEO, Michael B. Akoh said: "The launch of ArcticZymes T7 RNA Polymerase is an
important addition to our expanding Molecular Tools portfolio. Moreover, it is
the first of a portfolio of RNA enzymes that will allow us to tap into a growing
market for RNA therapeutics."

For more information, please contact:

CEO, Michael Akoh   Tel: +46 70 262 37 15
CFO, Børge Sørvoll     Tel: +47 952 90187
                       ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
The company is listed on the Oslo Stock Exchange since 2005 as ArcticZymes
Technologies under the [AZT] ticker. Its headquarters are based in Tromsø,
Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents. For more information, please visit the website:
www.arcticzymes.com

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange